Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis
- Resource Type
- Authors
- Black, DM; Bilezikian, JP; Greenspan, SL; Wüster, C; Muñoz-Torres, M; Bone, HG; Rosen, CJ; Andersen, HS; Hanley, DA
- Source
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol 24, iss 4
- Subject
- Aging
Clinical Trials and Supportive Activities
Clinical Sciences
PTH(1-84)
Biomedical Engineering
Medication Adherence
Endocrinology & Metabolism
Postmenopausal osteoporosis
Double-Blind Method
Bone Density
Clinical Research
80 and over
Humans
Aged
Lumbar Vertebrae
Bone Density Conservation Agents
Femur Neck
Evaluation of treatments and therapeutic interventions
Lumbar spine BMD
Middle Aged
Recombinant Proteins
Radius
Treatment Outcome
Parathyroid Hormone
Adherence
6.1 Pharmaceuticals
Musculoskeletal
Public Health and Health Services
Osteoporosis
Spinal Fractures
Hip Joint
Postmenopausal
Female
Bone Remodeling
Vertebral fracture
Osteoporotic Fractures
Biomarkers
Follow-Up Studies
- Language
UnlabelledThe purpose of this study is to examine the effect of PTH(1-84) treatment over 24 months followed by 12 months discontinuation on BMD, bone turnover markers, fractures and the impact of adherence on efficacy.IntroductionThere is limited information about the effect of PTH(1-84) after 18 months and limited data about the impact of compliance on response to anabolic therapy.MethodsSeven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment. Endpoints examined included changes in BMD and biochemical markers.ResultsPTH(1-84) treatment over 24 months increased BMD at the lumbar spine by 6.8% above baseline (p